Table 1.
Anticancer activity of hexacyclic CPTs against eleven human cancer cell lines.
| Cell line | Compound IC50 (μM) a | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Topotecan | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | |
| A549 | 1.424 | 1.028 | 2.057 | 2.169 | 1.394 | 1.124 | 3.371 | 1.502 | 0.092 | 0.170 | 1.832 | 6.472 |
| MCF-7 | 2.135 | 1.157 | 2.314 | 10.846 | 4.640 | 2.135 | 7.865 | 6.438 | > 10 | > 10 | > 10 | > 10 |
| MDA-MB-231 | 1.898 | 0.488 | 1.542 | 1.323 | 1.439 | 0.562 | 2.135 | 1.996 | 0.348 | 0.425 | 0.641 | 5.016 |
| HepG-2 | 0.237 | 0.064 | 0.180 | 1.106 | 0.016 | 0.063 | 0.079 | 0.071 | 0.055 | 0.060 | 0.348 | 0.971 |
| KB | 2.610 | 3.342 | 2.571 | 9.761 | 2.204 | 2.247 | 2.202 | 2.039 | 0.916 | 0.935 | 7.143 | 7.282 |
| BEL-7402 | 7.118 | 10.54 | 2.442 | > 10 | 3.480 | 2.022 | 2.135 | 1.931 | 0.275 | 0.425 | 2.015 | > 10 |
| SMMC-7721 | 11.627 | > 10 | 3.085 | > 10 | 10.441 | > 10 | 11.011 | > 10 | > 10 | 8.503 | > 10 | > 10 |
| MGC80-3 | 0.190 | 0.514 | 0.231 | 0.390 | 0.018 | 0.085 | 0.090 | 0.054 | 0.064 | 0.062 | 0.275 | 0.971 |
| SK-N-SH | 0.093 | 0.463 | NT b | 0.325 | NT b | NT b | NT b | NT b | 0.348 | 0.51 | 0.549 | 0.194 |
| QGY-7703 | 11.864 | > 10 | 11.568 | > 10 | 11.601 | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 |
| SGC-7901 | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 |
a
Values are the mean of at least three data points.
b
Not Tested.